VPBT — ProFund VP Biotechnology
Data updated: 2026-05-20
VPBT — ProFund VP Biotechnology data: holdings, portfolio allocation, expenses, performance, cashflows, risk and SEC filings. United States Health Care Equity · $41.74M AUM · 1.60% expense ratio · 56.1% 1-yr return. From SEC regulatory filings.
VPBT Fund Overview
VPBT — ProFund VP Biotechnology is a US mutual fund managed by ProFunds, categorised as United States Health Care Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US mutual fund
- Manager: ProFunds
- Category: United States Health Care Equity
- Assets under management: $41.74M
- 1-year return: 56.1%
- Ticker: VPBT
- SEC CIK: 0001039803
- SEC series ID: S000003965
- Share class ID: C000011092
VPBT Holdings
Top 10 holdings of ProFund VP Biotechnology by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| Agpxx | 2.39% |
| Apellis Pharmaceuticals Inc | 1.79% |
| Alkermes PLC | 1.41% |
| Madrigal Pharmaceuticals Inc | 1.35% |
| TG Therapeutics Inc | 1.32% |
| Insmed Inc | 1.30% |
| Scholar Rock Holding Corp. | 1.26% |
| Apogee Therapeutics Inc. | 1.25% |
| Protagonist Therapeutics Inc | 1.21% |
| Summit Therapeutics Inc. | 1.21% |
VPBT Portfolio Allocation
Asset-class allocation of ProFund VP Biotechnology by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 97.3% |
| Cash & Equivalents | 4.6% |
| Derivatives | 0.1% |
VPBT Performance
Total returns for VPBT (as of 2026-08-01), from SEC filings.
| Period | Total return |
|---|---|
| YTD | 4.4% |
| 1 year | 56.1% |
| 3 years (annualised) | 17.7% |
| 5 years (annualised) | 9.8% |
VPBT Risk Information
Risk metrics for VPBT, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 17.5%
VPBT Costs and Fees
VPBT costs about $160 per $10,000 invested per year in fund expenses.
- Net expense ratio: 1.60%
- Gross expense ratio: 1.60%
- Portfolio turnover: 222%
- Brokerage commissions: 5.45 bps of average net assets (SEC N-CEN)
VPBT Cashflows
Over the 12 months to 2026-03, ProFund VP Biotechnology had net outflows of $1.24M, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2026-03 | −$2.12M |
| 2026-02 | −$870.94K |
| 2026-01 | $1.74M |
| 2025-12 | −$357.63K |
| 2025-11 | $823.30K |
| 2025-10 | −$559.87K |
VPBT Debt Constituents
No individual debt constituents are reported in ProFund VP Biotechnology's latest SEC N-PORT filing.
VPBT Prospectus and SEC Filings
Official ProFund VP Biotechnology filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
Related Funds
Other United States Health Care Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.